Literature DB >> 21208112

Antibiotic therapy for the irritable bowel syndrome.

Jan Tack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21208112     DOI： 10.1056/NEJMe1011211

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Rifaximin for treatment of irritable bowel syndrome.

Authors:  Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-03

2.  Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO).

Authors:  Bani Chander Roland; Maria M Ciarleglio; John O Clarke; John R Semler; Eric Tomakin; Gerard E Mullin; Pankaj Jay Pasricha
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

3.  A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth.

Authors:  Bani Chander Roland; Gerard E Mullin; Monica Passi; Xi Zheng; Ahmed Salem; Robert Yolken; Pankaj Jay Pasricha
Journal:  Dig Dis Sci       Date:  2017-09-04       Impact factor: 3.199

Review 4.  Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.

Authors:  Rafael Tojo; Adolfo Suárez; Marta G Clemente; Clara G de los Reyes-Gavilán; Abelardo Margolles; Miguel Gueimonde; Patricia Ruas-Madiedo
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 5.  Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.

Authors:  Kang Nyeong Lee; Oh Young Lee
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.

Authors:  Rafid Kasir; Salam Zakko; Philip Zakko; Michael Adler; Aaron Lee; Sachin Dhingra; Cecile Guttermuth
Journal:  Dig Dis Sci       Date:  2015-09-11       Impact factor: 3.199

7.  Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach.

Authors:  J Kountouras; D Sofianou; E Gavalas; E Sianou; C Zavos; G Meletis; E Tsiaousi
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

8.  Intestinal microbiota in functional bowel disorders: a Rome foundation report.

Authors:  Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal
Journal:  Gut       Date:  2012-06-22       Impact factor: 23.059

9.  Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.

Authors:  William D Chey; Monthira Maneerattaporn; Richard Saad
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

10.  Targeted therapies for diarrhea-predominant irritable bowel syndrome.

Authors:  Kevin W Olden
Journal:  Clin Exp Gastroenterol       Date:  2012-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.